Principal Distribution Amount Definition & Meaning | Financial Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Principal Distribution Amount

Financial Term

Principal Distribution Amount (PDA) is a term used in financial accounting and investment management that refers to the amount of principal that is distributed to investors in a given period. In simple terms, it is the amount of money that an investor receives back from an investment, not including any interest or dividends earned.

PDA is an important metric in the financial industry as it helps investors understand the return on their investment in terms of the principal amount. It is often used in conjunction with other metrics like Internal Rate of Return (IRR) and Time-Weighted Rate of Return (TWRR) to evaluate the performance of investments.

Investment managers use PDA to determine the amount of principal to distribute to investors in a given period. They may also use it to assess the suitability of an investment for a particular client based on their investment objectives and risk tolerance.

In mutual funds, PDA is calculated by deducting any expenses incurred by the fund from the net asset value (NAV) of the fund. The remaining amount is then distributed to the investors based on their share of the fund.

Overall, PDA is a useful metric for investors and investment managers alike as it provides a clear understanding of the returns generated by an investment, enabling them to make more informed investment decisions.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P